FDA approves overactive bladder treatment Myrbetriq™ (mirabegron) from Astellas

Tweet

NORTHBROOK, IL USA (Press Release) - June 28, 2012 -

Myrbetriq is the first and only beta-3 adrenergic agonist indicated for the treatment of overactive bladderTo read more, a FREE Urotoday registration is required. Click here to register or login above.
To read UIJ content, a separate subscription is required.